Effect of cadmium fluoride and quercetin on in vivo activity of indoleamine 2,3-dioxygenase in mice liver and kidney

Fluoride

Volumn 47, Issue 1, 2014, Pages 31-42

  Zargar, Seema ^a,b   Siddiqi, Nikhat Jamal ^a,b   Khan, Tajdar Husain ^a,c   Elredah, Islam Eldin ^a,d  

^a Department of Biochemistry College of Science King Saud University ^*

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cadmium fluoride; Indoleamine 2,3 dioxygenase; Kidney; Liver; Quercetin

Indexed keywords

INDOLEAMINE 2, 3 DIOXYGENASE; QUERCETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; ENZYME ACTIVITY; FEMALE; MALE; MOUSE; NONHUMAN; PROTEIN CONTENT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84900871625     PISSN: 00154725     EISSN: 22534083     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364 (1): 82-90.
2. Fuchs D, Forsman A, Hagberg L, Larsson M, Norkrans G, Reibnegger G, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 1990; 10 (6): 599-603.
3. Andersson LM, Hagberg L, Fuchs D, Svennerholm B, Gisslen M. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individual-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 2001; 7 (6): 542-7.
4. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9 (10): 1069-77.
5. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196 (4): 447-57.
6. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002; 196 (4): 459-68.
7. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189 (9): 1363-72
8. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164 (7): 3596-9.
9. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103 (12): 4619-21.
10. Thomas SR, Stocker R. Redox reactions related to indoleamine 2, 3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999; 4 (5): 199-220.
11. Christen S, Thomas SR, Garner B, Stocker R. Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway. J Clin Invest 1994; 93 (5): 2149-58.
12. Soni MG, Kachole MS, Pawar SS. Alterations in drug metabolizing enzymes and lipid peroxidation in different rat tissues by fluoride. Toxicol Lett 1984; 21 (2): 161-72.
13. Mishra SK, Singh P, Rath SK. Protective effect of quercetin on chloroquine induced oxidative stress and hepatotoxicity in mice. Malaria Research and Treatment 2013; http: // dx. doi. org/10. 1155/2013/141734.
14. Kudo Y, Boyd CAD. Human placental indoleamine 2, 3 dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim Biophys Acta 2000; 1500 (1): 119-24.
15. Markwell MAK, Hass SM, Biebber LL, Tolbert, NE. A modification of Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978; 87 (1): 206-10.
16. Yamamoto S, Hayaishi O. Tryptophan pyrrolase of rabbit intestine. D-and L-tryptophancleaving enzyme or enzymes. J Biol Chem 1967; 242 (22): 5260-6.
17. Takikawa O. Biochemical and medical aspects of the indoleamine 2, 3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005; 338 (1): 12-9.
18. Chen XQ, Machida K, Isizaki K, Nisio N, Ando M. Pulmonary effects of sodium fluoride aerosol on rats. Fluoride 2000; 33 (4): 159-67.
19. Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation [review]. Adv Exp Med Biol 1996; 398: 285-9.
20. Hayaishi O, Hirata F, Ohnishi T, Henry JP, Rosenthal I, Katoh A. Indoleamine 2, 3-dioxygenase: incorporation of 18O2-and 18O2 into the reaction products. J Biol Chem 1977; 252 (10): 3548-50.
21. Shubhangi KP, Rajani GT, Aruna AJ. Neopterin: biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseases. Indian J Occup Environ Med 2008; 12 (3): 107-11.
22. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003; 198 (1): 153-60.
23. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2, 3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 129 (1-2): 186-96.
24. Wang S, Mao C, Zhao Z, Gu Q, Jin M, Xiao Y, et al. Increased TTS abrogates IDOmediated CD4+ T cells suppression in patients with Graves' disease. Endocrine 2009; 36 (1): 119-25.
25. Zhu L, Ji F, Wang Y, Zhang Y, Liu Q, Zhang JZ, et al. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol 2006; 177 (11): 8226-33.
26. Sophie S, Chen R, Lara C, Sinden SJ. Polyphenols inhibit indoleamine 3, 5-dioxygenase-1 enzymatic activity-a role of immunomodulation in chemoprevention. Discov Med 2012; 14 (78): 327-33
27. Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 1975; 9 (2-3): 229-34.